Home | Welcome to Contract Pharma   
Last Updated Monday, September 1 2014
Print RSS Feed

Biodel, Emergent BioSolutions Enter Glucagon Mfg. Pact



By Kristin Brooks



Published March 6, 2014
Related Searches: Development contractpharma.com Biopharma contractpharma
Biodel Inc. has signed a long-term manufacturing agreement with Cangene bioPharma Inc., doing business as Emergent BioSolutions, under which Emergent will fill and finish commercial quantities of a GEM device for use with glucagon. Financial terms were not disclosed.
 
Biodel’s GEM device is a customized version of Unilife's dual-chamber auto-reconstitution syringe, and is being developed for use as a rescue treatment for severe hypoglycemia. GEM is designed as an intuitive, easy-to-use device to address currently available kits that are considered difficult to assemble and operate during an emergency.
The fill/finish agreement, along with the previously-announced license and supply agreement for the GEM device with Unilife, and bulk glucagon supply agreement with Bachem, continue the company's preparation for the NDA submission anticipated in 2015 and subsequent commercial launch.
 
Dr. Errol De Souza, Biodel's president and chief executive officer, said, "We are pleased to reach another important milestone as we rapidly advance the commercialization of the first of our two unique glucagon rescue product candidates. We look forward to progressing through increasingly advanced stages of product development."
 


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On